Furthermore, our results show that a decrease in NSCLC by BR2-2xPPD is mediated, in part, through cell cycle G0/G1 arrest and a reduction in cyclin D1 and CDK2 expression in A549 NSCLC expressing wild-type EGFR (Fig 3). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.